Tech VCs drive cardiovascular imaging AI startup to A round

San Francisco (Pixabay)
San Francisco, Calif.

Bay Labs has raised $5.5 million to propel its artificial intelligence system for cardiovascular images toward the market. The technology is designed to support the performance and interpretation of echocardiograms, expanding the pool of physicians who can diagnose cardiovascular disease.

San Francisco, Calif.-based Bay Labs has tapped into the growing number of tech VCs with an interest in healthcare to bankroll its development. Existing investor Khosla Ventures led the series A round with assists from Data Collective (DCVC), Greenbox Venture Partners, Minneapolis Heart Institute Ventures and early Google employee Georges Harik.

The experimental technology in development at Bay Labs draws on resources including a library of 40 million videos to help healthcare professionals perform and interpret cardiovascular ultrasound scans. This support spans from input to helping the operator position the probe correctly to the automation of calculations including heart valve dimensions and the volume of blood pumped.   

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Bay Labs’ backers think its focus on ultrasound and AI puts it at an intersection with big potential. 

“Medical devices could see tremendous benefits from applying AI because they are static devices that produce hard-to-read data, which requires significant interpretation time from specialists,” Armen Vidian, DCVC operating partner, wrote in a blog post. “Ultrasound ... presents an ideal application for deep learning ... because of the high volume of nuanced structural information produced in every reading.”

Bay Labs is working with people at organizations including Minneapolis Heart Institute, Northwestern Medicine, Duke University School of Medicine and Stanford University to turn this idea into a commercial product. The series A positions Bay Labs to continue this validatory work. 

Suggested Articles

The FDA has cleared Drawbridge Health’s blood collection device designed to help monitor long-term blood sugar levels in people with diabetes.

FierceMedTech Fierce 15 winner 10x Genomics announced its plans for a $100 million IPO, on the Nasdaq using the symbol TXG.

Belgian devicemaker Miracor Medical received a breakthrough designation from the FDA for its treatment designed to limit the damage of a heart attack.